Research and Markets: Pruritus - Pipeline Review, H2 2014
December 19 2014 - 8:35AM
Business Wire
Research and Markets
(http://www.researchandmarkets.com/research/v7m9lq/pruritus) has
announced the addition of the "Pruritus - Pipeline Review, H2 2014"
report to their offering.
This report provides comprehensive information on the
therapeutic development for Pruritus, complete with comparative
analysis at various stages, therapeutics assessment by drug target,
mechanism of action (MoA), route of administration (RoA) and
molecule type, along with latest updates, and featured news and
press releases. It also reviews key players involved in the
therapeutic development for Pruritus and special features on
late-stage and discontinued projects.
This report features investigational drugs from across globe
covering over 20 therapy areas and nearly 3,000 indications. The
report is built using data and information sourced from This
proprietary databases, Company/University websites, SEC filings,
investor presentations and featured press releases from
company/university sites and industry-specific third party sources,
put together by This team.
Reasons to buy
- Provides strategically significant competitor information,
analysis, and insights to formulate effective R&D development
strategies
- Identify emerging players with potentially strong product
portfolio and create effective counter-strategies to gain
competitive advantage
- Develop strategic initiatives by understanding the focus areas
of leading companies
- Identify and understand important and diverse types of
therapeutics under development for Pruritus
- Plan mergers and acquisitions effectively by identifying key
players of the most promising pipeline
- Devise corrective measures for pipeline projects by
understanding Pruritus pipeline depth and focus of Indication
therapeutics
- Develop and design in-licensing and out-licensing strategies by
identifying prospective partners with the most attractive projects
to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued
projects and understanding the factors that drove them from
pipeline
Companies Mentioned:
- Amorepacific
- Cara Therapeutics
- Conrig Pharma
- Creabilis
- ELORAC
- FAES Farma
- GlaxoSmithKline
- Hydra Biosciences
- Johnson & Johnson
- LEO Pharma
- Merck & Co
- NeRRe Therapeutics
- Nippon Shinyaku
- RDD Pharma
- Santen Pharmaceutical
- Shionogi & Co
- Toray Industries
- Trevi Therapeutics
- Vanda Pharmaceuticals
For more information visit
http://www.researchandmarkets.com/research/v7m9lq/pruritus
Research and MarketsLaura Wood, Senior
Managerpress@researchandmarkets.comFor E.S.T Office Hours Call
1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT
Office Hours Call +353-1-416-8900U.S. Fax: 646-607-1907Fax (outside
U.S.): +353-1-481-1716Sector: Pharmaceuticals